Third generation EGFR TKIs: Current data and future directions

10.1186/s12943-018-0778-0

Saved in:

Bibliographic Details
Main Authors:	Tan, C.-S, Kumarakulasinghe, N.B, Huang, Y.-Q, Ang, Y.L.E, Choo, J.R.-E, Goh, B.-C, Soo, R.A
Other Authors:	DEPT OF PHARMACOLOGY
Format:	Review
Published:	2020
Subjects:	avitinib brigatinib circulating tumor DNA epidermal growth factor receptor epidermal growth factor receptor kinase inhibitor erlotinib fibroblast growth factor receptor 1 gefitinib K ras protein mavelertinib mitogen activated protein kinase naquotinib nazartinib olmutinib osimertinib pemetrexed phosphatidylinositol 3 kinase platinum derivative rociletinib unclassified drug yh 25448 piperazine derivative protein kinase inhibitor acne anemia C797S gene cancer growth cell transformation central nervous system metastasis circulating tumor cell decreased appetite diarrhea disease control drug development drug dose escalation drug dose increase drug efficacy drug indication drug resistance drug response drug safety drug selectivity drug tolerance drug withdrawal dry skin exon fatigue FGFR1 gene gene gene amplification gene mutation hepatitis B human hypertransaminasemia incidence interstitial lung disease maculopapular rash MAPK gene nausea non small cell lung cancer oncogene K ras paronychia patient-reported outcome PIK3CA gene pneumonia progression free survival pruritus QT prolongation rash Review rhinorrhea stomatitis T790 M gene tumor biopsy animal antagonists and inhibitors genetics metabolism mutation Animals Carcinoma, Non-Small-Cell Lung ErbB Receptors Humans Mutation Piperazines Protein Kinase Inhibitors
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/181215
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-181215
record_format	dspace
spelling	sg-nus-scholar.10635-1812152023-11-01T08:18:50Z Third generation EGFR TKIs: Current data and future directions Tan, C.-S Kumarakulasinghe, N.B Huang, Y.-Q Ang, Y.L.E Choo, J.R.-E Goh, B.-C Soo, R.A DEPT OF PHARMACOLOGY CANCER SCIENCE INSTITUTE OF SINGAPORE avitinib brigatinib circulating tumor DNA epidermal growth factor receptor epidermal growth factor receptor kinase inhibitor erlotinib fibroblast growth factor receptor 1 gefitinib K ras protein mavelertinib mitogen activated protein kinase naquotinib nazartinib olmutinib osimertinib pemetrexed phosphatidylinositol 3 kinase platinum derivative rociletinib unclassified drug yh 25448 osimertinib piperazine derivative protein kinase inhibitor acne anemia C797S gene cancer growth cell transformation central nervous system metastasis circulating tumor cell decreased appetite diarrhea disease control drug development drug dose escalation drug dose increase drug efficacy drug indication drug resistance drug response drug safety drug selectivity drug tolerance drug withdrawal dry skin exon fatigue FGFR1 gene gene gene amplification gene mutation hepatitis B human hypertransaminasemia incidence interstitial lung disease maculopapular rash MAPK gene nausea non small cell lung cancer oncogene K ras paronychia patient-reported outcome PIK3CA gene pneumonia progression free survival pruritus QT prolongation rash Review rhinorrhea stomatitis T790 M gene tumor biopsy animal antagonists and inhibitors genetics metabolism mutation Animals Carcinoma, Non-Small-Cell Lung ErbB Receptors Humans Mutation Piperazines Protein Kinase Inhibitors 10.1186/s12943-018-0778-0 Molecular Cancer 17 1 29 2020-10-27T10:14:05Z 2020-10-27T10:14:05Z 2018 Review Tan, C.-S, Kumarakulasinghe, N.B, Huang, Y.-Q, Ang, Y.L.E, Choo, J.R.-E, Goh, B.-C, Soo, R.A (2018). Third generation EGFR TKIs: Current data and future directions. Molecular Cancer 17 (1) : 29. ScholarBank@NUS Repository. https://doi.org/10.1186/s12943-018-0778-0 14764598 https://scholarbank.nus.edu.sg/handle/10635/181215 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	avitinib brigatinib circulating tumor DNA epidermal growth factor receptor epidermal growth factor receptor kinase inhibitor erlotinib fibroblast growth factor receptor 1 gefitinib K ras protein mavelertinib mitogen activated protein kinase naquotinib nazartinib olmutinib osimertinib pemetrexed phosphatidylinositol 3 kinase platinum derivative rociletinib unclassified drug yh 25448 osimertinib piperazine derivative protein kinase inhibitor acne anemia C797S gene cancer growth cell transformation central nervous system metastasis circulating tumor cell decreased appetite diarrhea disease control drug development drug dose escalation drug dose increase drug efficacy drug indication drug resistance drug response drug safety drug selectivity drug tolerance drug withdrawal dry skin exon fatigue FGFR1 gene gene gene amplification gene mutation hepatitis B human hypertransaminasemia incidence interstitial lung disease maculopapular rash MAPK gene nausea non small cell lung cancer oncogene K ras paronychia patient-reported outcome PIK3CA gene pneumonia progression free survival pruritus QT prolongation rash Review rhinorrhea stomatitis T790 M gene tumor biopsy animal antagonists and inhibitors genetics metabolism mutation Animals Carcinoma, Non-Small-Cell Lung ErbB Receptors Humans Mutation Piperazines Protein Kinase Inhibitors
spellingShingle	avitinib brigatinib circulating tumor DNA epidermal growth factor receptor epidermal growth factor receptor kinase inhibitor erlotinib fibroblast growth factor receptor 1 gefitinib K ras protein mavelertinib mitogen activated protein kinase naquotinib nazartinib olmutinib osimertinib pemetrexed phosphatidylinositol 3 kinase platinum derivative rociletinib unclassified drug yh 25448 osimertinib piperazine derivative protein kinase inhibitor acne anemia C797S gene cancer growth cell transformation central nervous system metastasis circulating tumor cell decreased appetite diarrhea disease control drug development drug dose escalation drug dose increase drug efficacy drug indication drug resistance drug response drug safety drug selectivity drug tolerance drug withdrawal dry skin exon fatigue FGFR1 gene gene gene amplification gene mutation hepatitis B human hypertransaminasemia incidence interstitial lung disease maculopapular rash MAPK gene nausea non small cell lung cancer oncogene K ras paronychia patient-reported outcome PIK3CA gene pneumonia progression free survival pruritus QT prolongation rash Review rhinorrhea stomatitis T790 M gene tumor biopsy animal antagonists and inhibitors genetics metabolism mutation Animals Carcinoma, Non-Small-Cell Lung ErbB Receptors Humans Mutation Piperazines Protein Kinase Inhibitors Tan, C.-S Kumarakulasinghe, N.B Huang, Y.-Q Ang, Y.L.E Choo, J.R.-E Goh, B.-C Soo, R.A Third generation EGFR TKIs: Current data and future directions
description	10.1186/s12943-018-0778-0
author2	DEPT OF PHARMACOLOGY
author_facet	DEPT OF PHARMACOLOGY Tan, C.-S Kumarakulasinghe, N.B Huang, Y.-Q Ang, Y.L.E Choo, J.R.-E Goh, B.-C Soo, R.A
format	Review
author	Tan, C.-S Kumarakulasinghe, N.B Huang, Y.-Q Ang, Y.L.E Choo, J.R.-E Goh, B.-C Soo, R.A
author_sort	Tan, C.-S
title	Third generation EGFR TKIs: Current data and future directions
title_short	Third generation EGFR TKIs: Current data and future directions
title_full	Third generation EGFR TKIs: Current data and future directions
title_fullStr	Third generation EGFR TKIs: Current data and future directions
title_full_unstemmed	Third generation EGFR TKIs: Current data and future directions
title_sort	third generation egfr tkis: current data and future directions
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/181215
_version_	1781792452976312320

Third generation EGFR TKIs: Current data and future directions

Similar Items